• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Atritech

edit

Atritech is a private company located in Minneapolis, Minnesota. The company was founded in 2000 and has developed proprietary technology focused on replacing long term anticoagulation therapy for patients with non-valvular atrial fibrillation at risk of stroke. The first implants of the WATCHMAN® Left Atrial Appendage Closure Technology were performed in Germany in August of 2002 and in the United States in October of 2003. Since then the company has conducted a large randomized clinical trial comparing the WATCHMAN® Left Atrial Appendage Closure Technology to long term Warfarin therapy in patients with non-valvular atrial fibrillation at risk of stroke. The WATCHMAN® Device is CE Marked and available in many markets outside the United States. The WATCHMAN® Device is currently available For Investigational Use Only in the United States.

Recent Milestones

edit

• 
  Atritech was acquired by Boston Scientific for $375M. (1/20/11)
  Posted 1/19/11 at 10:50pm via dowjones.com
• 
  Atritech added Jim Bullock as President and CEO.
  Posted 1/19/11 at 10:45pm

Videos

Screenshots

edit

Sources

1. Boston Scientific To Acquire Device Maker Atritech For Up To $375M (fis.dowjones.com) [edit]